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Background: Cronobacter can cause severe, invasive infection in very young infants. 
These bacteria can also colonize or cause insignificant infections in immunocompro-
mised, elderly, and/or hospitalized adults.
Methods: This editorial review highlights key points addressed in the Frontiers 
Research Topic on Cronobacter, discusses the clinical presentation and epidemiology 
of Cronobacter infections, and examines the responses of public health agencies to this 
problem.
Results: Cronobacter is rarely isolated from hospitalized, immunocompromised and/or 
elderly adults and does not cause significant disease in those patients. Certain species 
and strains, especially of Cronobacter sakazakii, can cause invasive illness in previously 
healthy infants <2 months of age. Multilocus sequence type 4 and clonal complex 4 
(ST4/MLST 4) C. sakazakii are the predominant cause of Cronobacter meningitis, which 
occurs only in infants. These infections and this strain type are strongly linked to powdered 
infant formulas (PIF), which can also be contaminated with other Cronobacter strains. 
End-product testing is not intended to guarantee the absence of these organisms. WHO 
has made recommendations that can help decrease but will not eliminate the risk of this 
infection.
Conclusion: To further define the spectrum of Cronobacter-associated disease, all 
isolates should be genetically typed using every currently available method, typing 
results should be linked to the associated epidemiologic and clinical data, and these 
data should be analyzed in a scientifically sound manner. Based on currently available 
information, more can be done now to prevent cause invasive infection in young infants. 
This includes encouragement of exclusive breastfeeding and/or use of commercially 
sterile ready-to-feed formulas in the first 2 months of life.
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BACKGROUND
Cronobacter are Gram-negative, non-spore-forming, enteric 
coliform bacteria defined as a new Enterobacter species in 1980 
by Farmer et  al. (1). Recently, polyphasic taxonomic analysis 
has determined that this group of organisms consists of several 
genomospecies, so these organisms have been reclassified as 
novel species and subspecies within a novel genus, Cronobacter 
gen. nov. (2). Cronobacter isolates vary in regard to enterotoxin 
production, virulence, and thermotolerance. These varia-
tions – and Cronobacter’s taxonomy, ecology, reservoirs in nature, 
and characteristics in general  –  are almost certainly of clinical 
importance but have not been adequately studied and are not 
fully understood. Of the strains examined, many are extremely 
heat tolerant and can survive for long periods of time in a dry state 
[e.g., Ref. (3, 4)]. At least some form biofilms and thus resist the 
effectiveness of disinfectants (3–5). Lag times and microbiologic 
incubation periods for some Cronobacter strains can be as low as 
a matter of hours (6–8). In one study, an initial concentration of 
only 1 colony forming unit (CFU)/ml of Enterobacter sakazakii in 
reconstituted PIF grew to 10,000,000 in 10 h, at room temperature 
(9). Of note, growth would be even faster at body temperature.
Cronobacter are rarely isolated from clinical specimens and, 
when isolated, are largely from the very young or the elderly. Some 
strains can be highly pathogenic in neonates, especially infants who 
are premature or otherwise immunocompromised. Cronobacter 
occasionally colonize immunocompromised and/or elderly adults 
who are infected with other, significant pathogens. In these adults, 
Cronobacter rarely, if ever, cause significant symptomatic disease. 
In neonates, some strains of Cronobacter (and, in particular, some 
strains of C. sakazakii) cause invasive infection, even though the 
initial isolate is often from the gastrointestinal tract. The presen-
tations and outcomes of neonatal C. sakazakii infection include 
seizures, hydrocephalus, developmental delay, and death.
A number of gastrointestinal and immunologic characteristics 
can contribute to an infant’s susceptibility to invasive C. sakazakii 
infection. First, the stomach environment of newborns, especially 
of premature babies, is less acidic than that of adults. Gastric and 
pancreatic secretions, mucus, and inherent enzymes are not pro-
duced at the levels found in an adult’s gastrointestinal tract. This 
would more readily permit any C. sakazakii entering the body 
through the mouth to survive in a viable state as it moves from 
the infant’s stomach to his intestines. Second, although enteric 
neuronal development is generally completed at a gestational 
age of 32 weeks (10), ineffective, uncoordinated, erratic, or static 
gut motility (peristalsis) can persist at least intermittently in 
even full-term infants. Peristalsis is an important mechanism 
for moving pathogenic organisms through and out of the gut, 
so dysfunctional movement may be a factor in C. sakazakii 
breaching the intestinal wall. Third, a fetus’s gut is sterile but 
this changes with passage through the maternal birth canal and 
first feeding. A newborn infant’s gastrointestinal system remains 
functionally inert until it is activated by food intake and microbial 
colonization. This means that until feeding is stably established, 
the feedback system between an infant’s gut and gut organisms 
does not function properly. Until then, an infant’s gut has sub-
optimal bacterial-epithelial “cross-talk,” i.e., a relative inability to 
differentiate pathogens from symbiotic organisms and to deal with 
each appropriately (11). Fourth, even if C. sakazakii is recognized 
as an enemy, an infant’s relatively permeable mucosa make him 
less able to retain the organism in his gastrointestinal system and 
remove it from his body. Last and perhaps most important, gut 
immunity develops gradually between fetal life and adulthood. 
Premature newborns, full-term newborns (born at 37–42 weeks 
gestation), neonates (<28 days old), and older infants (more than 
28 days but <1 year old) differ significantly from one another and 
from older children and adults in regard to adequacy, strength, 
pattern, components, and rapidity of their immune response 
(11–13). Neutrophils can disrupt the intestinal tight junctions by 
releasing excessive interleukin (IL)-8 (12). Innate immunity, as 
represented by Natural Killer Cell (NK) production of interferon 
(IFN)-γ, dominates in early life (13).
The reservoirs for Cronobacter species are unknown. The 
majority of E. sakazakii and C. sakazakii isolates have come 
from infants, powdered infant formulas (PIFs), and factories 
producing milk powder (14). Cronobacter species have also 
been isolated from a number of other food substances [e.g., Ref. 
(4, 15)], food factories, and environments, including households 
(16); however, to my knowledge, no non-formula source of E. 
sakazakii or C. sakazakii has yet been causally linked to a case of 
invasive infection, although other sources have been examined in 
epidemiologic investigations.
THe ePiDeMiOLOGY OF  
CRONOBACTER iNFeCTiON
In Dr. Farmer’s first-hand review of Cronobacter’s microbiologic 
history (17), he appropriately credits Drs. Urmenyi and Franklin 
with the first clinical descriptions of invasive E. sakazakii disease, 
a description provided in a 1961 report of two 1958 cases of 
“neonatal death from pigmented coliform infection” (18). Those 
infants were born within months of each other, at a single United 
Kingdom hospital. Both developed hemorrhagic meningitis 
and died within 2  days of one another. One was full term, of 
normal birthweight, and had been discharged home. The other 
was premature, had low birthweight, and was still in the birth 
hospital when his symptoms began. Post mortem cultures from 
both infants grew identical “pigmented cloaca.” The infants had 
no known contact with one another and had not been on the 
same ward or nursery (18). In 1965, Jøker et al. reported a similar 
case, this time in Denmark. Dr. Farmer’s review article in this 
Frontiers Topic symposium describes how, over the following 
two decades, those isolates and similar pigmented coliforms 
were characterized, differentiated from other Enterobacter, and, 
in 1980, officially named Enterobacter sakazakii, according to the 
rules of the Bacteriological Code (17).
In the subsequent two decades, Cronobacter microbiologic 
research progressed but epidemiologic studies came to the 
forefront, in the form of outbreak investigations of pediatric 
E. sakazakii infections in the Netherlands (1983), Greece 
(1987), Iceland (1989), the United States [U.S.] (1989 and 
2001), Belgium (2001), Israel (2001), France (2004), and New 
Zealand (2004) (19–21). In the early investigations, no source 
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was identified. Tellingly, nutrition was not examined in those 
outbreaks. The  investigations of subsequent outbreaks repeat-
edly documented a strong statistical and microbiological link 
between PIF and invasive E. sakazakii infection. The outbreak 
studies were increasingly elegant and thorough. In all 10 out-
breaks, at least some environmental testing had been done. In 
the eight outbreaks in which nutrition was examined, all the 
infected infants had received some type of PIF and there was a 
statistically powerful association between E. sakazakii infection 
and consumption of a specific PIF. In five outbreaks, E. sakazakii 
was isolated from PIF but not from any environmental samples; 
in two, E. sakazakii was isolated from PIF and the blender 
used in blending that specific PIF; and in one, E. sakazakii 
was isolated from PIF, a dish brush, and a stirring spoon. Four 
outbreak reports specified that previously unopened containers 
of PIF were cultured; of these, three were positive. In seven of the 
eight outbreaks where E. sakazakii was typed, a PIF isolate was 
indistinguishable from patient isolate(s), based on the results 
from one or another of the typing techniques summarized in 
Dr. Yan’s concise article in this Frontiers symposium (22). The 
formula consumed by infected infants in each of these outbreaks 
yielded E. sakazakii; in two outbreaks, formula from previously 
unopened cans from the same manufacturing batch also yielded 
E. sakazakii. In three outbreaks, investigators were able to show 
both statistical and microbiological associations between E. 
sakazakii infection and the consumption of PIF (23–25). In 
these investigations, there was no evidence of infant-to-infant 
or environmental transmission; all the infected infants had 
consumed the implicated formula (23–25).
At the time these investigations were done, epidemiologists 
had reason to suspect that E. sakazakii infections might be caused 
by a nutritional substance. Entero is derived from the Greek word 
for intestines. Enterobacter got that name because they have long 
been known to enter the body through the digestive system and 
reside in the intestines. There was also good reason to consider 
PIF as the potential nutritional source of these E. sakazakii 
infections. Infants are fed PIF and PIF is not sterile. Studies had 
already shown that strains of E. sakazakii could contaminate 
PIF components, become endemic in the post-pasteurization 
dry-processing areas of PIF processing plants, survive the dry-
processing procedures, survive in a dry state for long periods of 
time, and become biologically active in the presence of moisture. 
Thus, it did not require great insight to include PIF as one of the 
independent variables studied in these outbreaks. However, these 
studies do demonstrate the elegant effectiveness of interactively 
applying epidemiologic, statistics, and microbiologic scientific 
techniques to outbreaks involving extremely few cases.
Concurrent with the above-described epidemiologic investiga-
tions, microbiologists and food scientists investigated the extent 
and nature of PIF contamination with E. sakazakii. Muytjens 
et al. examined 141 different powdered formulas on the market 
produced in 35 countries and found E. sakazakii and other 
Enterobacteriaceae were common contaminants (26). He isolated 
E. sakazakii at levels ranging from 0.36 to 66 CFU/100 g from 20 
formula samples from 13 countries (27), even though all those 
formulas met the contemporaneous microbiological specifica-
tions for coliform counts in PIF (<3 CFU/g). A Canadian survey 
that investigated the incidence of E. sakazakii in PIF isolated the 
organism from eight of 120 cans on the market, from five different 
manufacturers (28).
In 2002, a Belgian infant who received PIF died from an E. 
sakazakii infection. The manufacturer retested the implicated 
batch (also referred to as a “lot”) and, although the prerelease 
testing of the product had been negative for E. sakazakii, the 
additional testing was positive. The company voluntarily recalled 
the product. Following the epidemiologic investigation of a 
2001 U.S. newborn intensive care unit outbreak (23), a lot (also 
referred to as a “batch”) of the implicated product was recalled 
and the U.S. Food and Drug Administration (FDA) did a field 
survey of 10 U.S. powdered formula manufacturing plants run by 
various manufacturers (29). In that field survey, which included 
22 finished product samples, five (22.7%) had a most probable 
number (MPN) above what was then the currently acceptable 
detection limit (0.003 MPN per gram of PIF). The positive sam-
ples included four of 14 (28.5%) formulas for full-term and one 
of four (25%) formulas for pre-term infants. The results were 
not related to product type (milk vs. soy) or manufacturing 
processing used (e.g., wet mixing-spray drying vs. dry blending) 
(29). Despite these findings, infant formula manufacturers did 
not readily accept that their products played any role in these 
infections or were of any risk to healthy, full-term infants (30). 
Public health and regulatory agencies did not fully agree with the 
manufacturers.
In 2002, the FDA released a protocol for isolation and 
enumeration of E. sakazakii from dehydrated PIF [formerly at 
http://www.fda.gov/Food/ScienceResearch/LaboratoryMethods/
BacteriologicalAnalyticalManualBAM/ucm109656.htm. 
No  longer available on at the FDA website.] The protocol was 
an improvement over formula companies’ standing protocols 
but had significant flaws and was worrisome in that it did not 
attempt to assure the absence of Cronobacter in end-product. 
Furthermore, the FDA did not require manufacturers to use 
the FDA protocol for PIF end-product testing, nor did the FDA 
address environmental testing.
Also in 2002, the FDA sent out a “Letter to Health Care 
Professionals,” informing them that PIF and powdered breast milk 
supplements are not sterile and warning that premature infants 
and infants with underlying medical conditions could become 
infected with E. sakazakii (31). In the letter, the FDA recom-
mended PIF be avoided in newborn intensive care units unless 
there was no alternative.
Parents of newborn or even of newborn premature infants have 
never received similar information, although, even at that time 
(i.e., 2002–2003) invasive E. sakazakii infection had occurred in 
term and non-hospitalized infants (21). There is reason to believe 
infants’ caretakers were then and remain in need of this infor-
mation: In a 2005–2006 nationally representative survey of U.S. 
mothers of 2-month-old infants, only 29.5% correctly answered 
that PIFs were “likely to contain germs,” while 31.1% incorrectly 
thought that commercially sterile, ready-to-feed formulas (RTFs) 
were likely to contain them (32). Of note, that survey was done 
after most, if not all, formula manufacturers had bowed to 
encouragement to educate the consumer by adding the statement 
“PIF is not sterile” to their package labels.
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Based on the accumulating epidemiologic evidence and 
product-testing data, the World Health Organization (WHO) 
acknowledged there was a problem that needed to be addressed. 
In 2004–2008, the Food and Agriculture Organization of the 
United Nations (FAO) and World Health Organization (WHO) 
held a series of advisory meetings concerning E. sakazakii (33, 
34). These resulted in a risk assessment model, as well as a 
series of reports and recommendations [FAO/WHO1]. In this 
Frontiers Topic symposium, Dr. Parra Flores applies the WHO’s 
risk assessment tool to explore the effect of temperature on 
Cronobacter growth (35). In 2006, WHO stated that “contami-
nated PIF has been convincingly shown, both epidemiologically 
and microbiologically, to be the vehicle and source of infection 
in infants” (36). However, WHO’s guidelines and model focus 
on decreasing the risk associated with contaminated PIF, not 
preventing the contamination.
Even as WHO was formulating a response to the Cronobacter 
problem, reports of intrinsic PIF contamination continued 
to be made to the European Rapid Alert System for Food and 
Feed (RASFF). Between 2002 and 2008, eleven lots of PIF were 
cleared and released for sale by their manufacturers, distributed 
in Europe, and subsequently reported by outside authorities to 
be contaminated with E. sakazakii (37). E. sakazakii infections 
and colonizations were reportedly associated with at least three 
of these contaminated products (37). At least one other lot was 
reported to RASFF, by France in 20092. Of note, the U.S. did not 
and does not have a reporting system for product contamination 
or infections with this organism. They are currently reportable 
in only one State  –  Minnesota (personal communication with 
Dr. A. Bowen, an epidemiologist at CDC, January 2012).
At the beginning of the twenty-first century, while health and 
regulatory agencies were developing models and guidelines, labo-
ratorians were making striking advances. Their research followed 
two avenues: (a) typing and characterization of isolates and (b) 
investigating, characterizing, and statistically evaluating PIF con-
tamination and end-product testing. These topics are addressed 
in this symposium’s articles by Dr. Yan and Dr. Kalyantanda (22, 
38) but, in the following paragraphs, this editorial review will 
briefly discuss what are arguably the two most significant devel-
opments to date: identification of highly stable C. sakazakii clone 
with a high propensity for neonatal meningitis and determination 
that pre-market PIF testing cannot assure an absence of clinically 
significant contamination.
As noted in Dr. Farmer’s review article in this Frontiers Topic 
symposium (17), in 2007–2008, Iverson et  al. proposed that 
Cronobacter be recognized as a new genus. That genus was to 
include organisms previously classified as E. sakazakii (2). As 
of this writing, 10 species and 3 subspecies of Cronobacter have 
been named and described. In their contribution to this sympo-
sium, Dr. Yan and Dr. Fanning succinctly describe the various 
and increasing number of laboratory techniques for identifying, 
tracking, comparing, and characterizing Cronobacter isolates 
1 ftp://ftp.fao.org/docrep/fao/009/a0707e/a0707e00.pdf and http://www.fstools.
org/esakmodel/ESAKRAModelWizard.aspx
2 http://ec.europa.eu/food/food/rapidalert/reports/week8-2009_en.pdf
(22, 38). Also in this Frontiers Topics symposium, Dr. Tall pre-
sents a pan genomic DNA microarray platform he developed and 
has used to document and characterize the genomic diversity 
among each member of the genus (39). That approach, as well 
as whole genome sequencing, will be powerful tools for genomic 
research on Cronobacter but one technique has already proved 
invaluable: a multi-locus sequence typing (MLST) scheme 
developed by Baldwin et al. (40). Application of that scheme to 
stored clinical, food, and environmental isolates has provided 
key information about the sources of various Cronobacter spe-
cies and strains, the cause of Cronobacter meningitis, and the 
reasons why infants have severe clinical symptoms and adults 
do not (40–42).
Baldwin determined sequence types in relation to source 
and biotype, using 60 C. sakazakii and 16 C. malonaticus strains 
from clinical and non-clinical sources collected between 1951 
and 2008 in the U.S., Canada, Europe, New Zealand, and the Far 
East. Twenty-two of 60 C. sakazakii isolates had sequence type 
4 (ST4). Nine of those ST4 isolates were from clinical samples. 
Seven of the other 13 ST4 isolates were from infant formula 
(40). Joseph and Forsythe examined 41 C. sakazakii isolates, 
some of which appear to have been among those described 
by Baldwin (40, 41). Twenty of the 41 isolates were ST4; the 
remainder were one or another of nine other types. Of the 30 C. 
sakazakii isolates with known patient-source details, the only 
one from an adult patient was ST1, i.e., not ST4. Of the 20 ST4 
strains, 10 were from neonates, seven from infants, one from a 
child, and two had no patient information. Although the seven 
housekeeping genes for MLST analysis are not virulence related, 
a large proportion of severe neonatal infections were caused by 
isolates with the ST4 sequence type: i.e., 9 of 12 isolates from 
meningitis cases were ST4 strains; the remaining ST4 strains 
were from a bacteremia case, necrotizing enterocolitis cases 
(two), and an undefined infection (one). The clinical disorders 
related to six of the ST4 strain isolates were unknown. Nine of 
12 meningitis isolates were ST4. Joseph and Forsythe concluded 
that C. sakazakii ST4 and the related Clonal Complex 4 (CC4) 
represent a highly stable clone with a high propensity for neona-
tal meningitis (41, 42). They noted that C. sakazakii ST4 strains 
have been isolated from seven countries for >50 years and the 
earliest (1950) non-clinical isolate was from a can of dried milk. 
Joseph and Forsythe proposed that the relationships between 
genotypes and different age groups may reflect exposure to dif-
ferent genotypes of C. sakazakii according to age-related diet 
and lifestyle. In the context of Baldwin and Forsythe’s finding 
of a predominance of ST4 types in C. sakazakii isolates from 
infant formulas, Joseph and Forsythe’s results suggest that the 
key exposure in C. sakazakii-infected infants is intrinsically 
contaminated infant formula.
Of note, in an FDA investigation of 14 cases of community–
acquired pediatric Cronobacter infections between May, 2010 and 
December, 2011, Dr. Tall et al. did ST typing. These isolates were 
not related to those previously studied by Dr. Baldwin et al. but 
they were also predominantly ST4 (43). MLST testing of isolates 
from numerous food and other sources from around the world 
is progressing at a rapid pace and indicates that MLST types vary 
by food and food-factory source, clinical source, and country. 
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As noted by Dr. Kalyantanda in this Frontiers Topic symposium, 
results are being posted at an online database3 (38).
By far, the most significant development related to product 
safety and testing was a 2011 study, done in collaboration with 
a European branch a formula manufacturing company (44). In 
it, Jongenburger et al. examined a production “lot” (also referred 
to as a “batch”) of PIF. That batch had passed pre-market testing 
and been released to market, but it was subsequently found to 
be contaminated with Cronobacter. The researchers compared 
the contaminated batch to one recalled for non-microbiologic 
reasons and determined that: (a) both lots were actually posi-
tive for Cronobacter but a greater number of samples from the 
contaminated lot were positive, (b) the contamination was not 
homogeneous, and (c) the recalled lot had higher levels of con-
tamination (44). The estimated degree of contamination varied 
among the positive samples and included clusters of 3–560 cells. 
The two largest clusters, of 123 and 560 cells, originated from 
two product bags only, consistent with clusters being present 
in a limited number of servings. Thus, an individual infant can 
be exposed to a significant inoculum, even if the remaining 
product in that can, the remaining product in that lot, and the 
product from that lot fed to other infants are free of Cronobacter. 
Dr. Jongenburger concluded that “finding such clusters is like look-
ing for a needle in a haystack” and “when these clusters end up in 
one or a limited number of servings of an individual consumer, they 
may significantly impact public health” (44).
Dr. Jongenburger’s findings are especially meaningful because 
the sparse research on Cronobacter’s infectious dose suggests it 
can quite low, i.e., on the order of 1000 cells (3, 45) and quite 
possibly even lower for virulent strains. Extensive research has 
been done on related parameters, including lag time, generation 
time, and growth rate. Unfortunately, this research has not yet 
been done using specific isolates associated with proven, invasive 
clinical infections, e.g., C. sakazakii ST4 or CC4 isolates associated 
with Cronobacter meningitis in young infants. However, using the 
data that are available, albeit for non-virulent isolates, we can get 
a sense of how quickly an infectious dose of 1000 cells can be 
reached when contamination is clustered or clumped. Let us take 
a relatively small cluster of 10 cells. (Of note, in end-product test-
ing, that cluster would appear as one CFU, even though all 10 cells 
could multiply independently.) Let us be conservative and round 
up the generation time determined by Dr. Parra Flores in his arti-
cle in this Frontiers Topic symposium (35), which is consistent 
with the value found by others. Using a generation time of a half 
hour at 35°C (a temperature roughly comparable to the 36–37°C 
body temperature of an afebrile neonate) and assuming virulent 
Cronobacter strains thrive in the neonatal gastrointestinal tract, 
the 10-cell cluster would reach an infectious dose of 1,000 CFU 
within 3.5 h, a time interval consistent with the time it takes an 
infant to consume and digest a formula feeding.
To summarize, by the end of 2011, it had been determined 
that Cronobacter meningitis is associated with ST4 strains of C. 
sakazakii, these strains are found widely throughout PIF and PIF 
production facilities, and they appear to be stable clones present 
3 http://pubmlst.org/Cronobacter/
for many years in many countries. Other Cronobacter can be 
found in PIF and PIF factories but the evidence thus far suggests 
they do not cause meningitis. Dry-product Cronobacter contami-
nation can be non-homogeneous, clustered, and clumped. End-
product testing is inadequate for preventing that contamination 
and isolated contamination could be present even if the batch 
were negative to end-product testing and every other can in the 
batch was negative.
This laboratory progress was scientifically significant but, in 
late 2011, epidemiology again came to the forefront – if only in 
regard to the public media. Single reports of Cronobacter illness 
in infants in Missouri and Illinois caused the U.S. Centers for 
Disease Control and Prevention (CDC) to ask public health 
officials around the country to look for other cases of Cronobacter 
infection among infants. This generated reports of two additional 
cases, one in Oklahoma and one in Florida, bringing the 2011 U.S. 
case total to 13 (46). According to CDC’s Cronobacter website, 
CDC investigated the four cases occurring after November 1, 
2011. All had been fed PIF, three had meningitis, and two died. 
The website indicates that CDC could not determine a source and 
DNA fingerprinting of isolates from two or the cases suggested 
they were unrelated. ST testing is not mentioned, nor if any of 
these cases were among those tested by Dr. Tall and found to be 
predominantly ST4, the strain type associated with both menin-
gitis and PIF (see above) (43). The CDC website indicates that 
factory-testing was negative and notes that “Cronobacter bacteria 
are found in the environment and in hospitals and homes.” These 
statements ignore the wide variety in Cronobacter species and 
strains, the ST studies, and the extensive epidemiologic evidence 
supporting that PIF is the primary source of the specific ST type 
causing most cases of invasive Cronobacter meningitis.
At the time these 2011 cases were reported to the general public, 
I had reviewed the Cronobacter literature and material from for-
mula manufacturers, as well as CDC, FDA, and WHO records and 
documents up to and through 2010, as well as the medical records 
of a number of Cronobacter cases that had not been investigated by 
those agencies. I was concerned that statements made in relation 
to these cases did not seem to match the material I had in hand. 
I therefore used that material to perform three epidemiologic 
analytic studies related to invasive E. sakazakii/Cronobacter infec-
tion. These studies were published as an article in Pediatrics, the 
peer-reviewed journal of the American Academy of Pediatrics (21). 
In this Frontiers  editorial review i will now  briefly describe those 
three epidemiologic studies and discuss how the findings and the 
current state of Cronobacter science are discordant with CDC’s cur-
rent approach to epidemiologic surveillance and investigations, as 
well as with the FDA’s current PIF and PIF factory surveillance and 
testing protocols.
Two of these epidemiologic studies examined data on all 
reported cases of pediatric E. sakazakii/Cronobacter infection 
occurring worldwide from 1958 through 2010. The two studies 
also analyzed in greater depth all cases of invasive infection 
occurring in children who appeared to have been previously 
healthy, i.e., without any known underlying immunodeficiency 
or disorder. “Invasive disease” was defined as necrotizing entero-
colitis, urinary tract infection, bacteremia, and/or meningitis, 
since this definition had been used in the previous Cronobacter 
FiGURe 1 | Proportion of infants with invasive Cronobacter infection 
and proportion of all U.S. neonates who are exclusively breastfed.
TABLe 2 | Number and proportion of reported infants without underlying 




1958–2003 2004–2010 Total P valued
Any PIF or HMF 51/54 (94%) 25/30 (83%) 76/84 (90%) NS
Any breast milk 10/54 (18%) 12/29 (41%) 22/83 (26%) P = 0.036 
Any RTF 6/53 (9%) 13/29 (45%) 19/82 (23%) P = 0.003
Any concentrate 1/53 (2%) 2/29 (7%) 3/82 (4%) NS
aDocumented nutrition at any time prior to onset of symptoms, based on the best 
available information, including from medical records, CDC files, parent report, 
publications, and communications with publication authors. PIF, powdered infant 
formula ; HMF, powdered human milk fortifier. Total percents may not equal 100 due to 
rounding. Denominators include only those for whom data were known.
bThis includes one infant who received formula that was likely but not definitely PIF and 
definitely did not receive breast milk (2000 case, personal communication, J. Burdette, 
October 6, 2011). This infant is included in the denominator for “any breast milk” and 
not in any numerators. The category also includes an infant who definitely received a 
recalled, contaminated lot of PIF but I could not determine if he received breast milk 
or other formulas as well (Belgium 2002). This infant is included in the numerator and 
denominator for “any PIF.” A third infant in this category is a term newborn recorded 
on a CDC line list as not having received PIF but without information concerning 
what, if any, enteral feeding she did receive (AZ 2009). This infant is included in the 
denominator of “Any PIF or HMF” and is not included in “Any breast milk,” “Any RTF,” 
and “Any concentrate.”
cCategories are not mutually exclusive; therefore, total percent is >100. Numbers are 
for those who had the specified nutrition noted.
dFisher’s exact tests. Not considered significant (NS) if P ≥ 0.05.
TABLe 1 | Age and diagnoses of all reported infants without underlying 
disorders, invasively infected with Cronobacter, by time period.
1958–2003 2004–2010 Total P valuea
Age at onset of symptoms
≤30 days/ 
1 month old
53/66 (80%) 27/30 (90%) 80/96 (83%) NS
≤60 days/ 
2 months old
65/66 (98%) 30/30 (100%) 95/96 (99%) NS
Diagnosesb
Meningitis 38/68 (56%) 22/30 (73%) 60/98 (61%) NS
Bacteremia 21/68 (31%) 14/30 (47%) 35/98 (36%) NS
NEC 22/68 (32%) 1/30 (3%) 23/98 (23%) P = 0.001
UTI 1/68 (2%) 0/30 (0%) 1/98 (1%) NS
aFisher’s exact tests and Freeman–Halton extension of the Fisher’s exact probability 
test for a 2 × 3 table. Not significant (NS) if P ≥ 0.05. Totals percents may not equal 
100 due to rounding.
bSome patients had more than one diagnosis. Specifically, 18 patients with meningitis 
also had proven bacteremia and 2 also had necrotizing enterocolitis (NEC). One patient 
with bacteremia also had NEC and one also had a urinary tract infection (UTI). P values 
are for proportion with each individual diagnosis.
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literature [e.g., Ref. (19, 20)]. My first study was an epidemiologic 
characterization of all reported cases of invasive E. sakazakii or 
Cronobacter infection occurring in previously healthy children 
in 1958–2010. The second was a statistical comparison of cases 
occurring in 1958–2003 to those occurring in 2004–2010, i.e., 
before and after the dissemination of the FDA’s “2002 Letter/
Revised Letter to Health Care Professionals,” in which the FDA 
recommended that “PIFs not be used in neonatal intensive care 
settings unless there is no alternative available” (31). As noted 
above, the FDA did not provide any guidance or recommenda-
tions to caretakers of infants living at home, even though cases 
had occurred in home settings by the time of the FDA’s Letter 
to Healthcare Professionals. The third study was a cross-sectional 
cost comparison of milk-based and soy-based: (a) PIF, (b) com-
mercially sterile RTF, and (c) commercially sterile concentrates 
(which are to be diluted one-to-one with water prior to feeding). 
This study included data on a variety of brands of formula. It 
was done in response to statements made by the FDA, manu-
facturers, and others, in which they acknowledge that properly 
manufactured RTF cannot infect infants but insist that using RTF 
is not an option because it is significantly more expensive than 
PIF. These spokespersons provide only anecdotal statements and 
outdated references for their opinion [see, for example, Ref. (47)]. 
Therefore, my third study was intended to provide substantive, 
current data rather than anecdotes.
There were several striking findings in the first analytic study. 
First, for the entire time period examined, only one previously 
healthy infant who became invasively infected was older than 
2  months of age at the time of symptom onset. Second, the 
majority of infected infants had meningitis and a third had docu-
mented bacteremia (Table 1). Third, 90% of invasively infected 
infants had received PIF at some point in time prior to onset 
of symptoms; this did not differ significantly between the two 
periods (Table 2). Only 4% of infants with invasive Cronobacter 
infection, worldwide, had been exclusively breastfed (EBF) 
(Figure  1). None of these breastfed infants resided in the U.S. 
but, for comparison: 46% of all U.S. neonates are EBF (48). Thus 
the proportion breastfed is much lower than would be expected, 
even if all the EBF infants had lived in the U.S.
The second set of analyses documented several significant 
differences between cases occurring in 2004–2010 compared 
to 1958–2003. The proportion with necrotizing enterocolitis, a 
disease that occurs in hospitalized premature infants, was signifi-
cantly lower in 2004–2010 (Table 1). This decrease is consistent 
with the following findings: in 2004–2010, a significantly higher 
proportion of invasively infected infants were full term, normal 
birthweight, and living at home when symptoms began (Table 3). 
Also, in 2004–2010, a significantly higher proportion of infected 
infants had been given multiple types of nutrition prior to onset of 
symptoms (Table 2). This was largely due to their receiving RTF 
in their birth hospital and being switched to PIF at home (data 
TABLe 4 | Per ounce price and price difference, by type and form of 
infant formula, comparing least-expensive available product in stated 
categorya,b.
Actual cost/ouncec Actual cost differences 
compared to powdered
Milk-based formula:
 Powdered 0.121 NAd NA 
 Ready-to-Feed 0.156 29% 0.035
 Concentrate 0.137 13% 0.016
Soy-based formula:
 Powdered 0.140 NA NA
 Ready-to-Feed 0.130 -7% -0.010
 Concentrate 0.140 0% 0
aCosts were determined for six formulas available for neonates and young infants (and 
for use by a premature or immunocompromised infant as/if recommended by that 
infant’s pediatrician): Enfamil (milk-based) (five stores for PIF and RTF, two stores for 
concentrate); ProSobee LIPIL (soy-based) (five stores for PIF, three stores for RTF, and 
two stores for concentrate); good start with iron, gentle or gentle plus (milk-based) 
(n = 5 stores for PIF, four stores for RTF, and three stores for concentrate); Good 
Start soy, Supreme or Supreme Plus (four stores for PIF, three stores for RTF, and two 
stores for concentrate); Similac Advance (milk-based) (five stores for PIF, RTF, and 
concentrate); and Isomil (soy-based) (five stores for PIF, four for RTF and concentrate). 
Prices were obtained in September 2011, for the least expensive packaging options, 
from the following internet sites: Amazon.com, Babies-R-Us, CVS, Diapers.com, and 
Walmart. Not all sites carried all brands of each product but all sites carried at least one 
brand each of a powdered, ready-to-feed, and concentrate product. Price ranges are 
for any of the assessed brands at any of the assessed internet sites.
bLowest priced product of any brand, at any store. Numbers reflect actual costs and 
cost differences for those products.
cIn dollars per fluid ounce of prepared formula.
dNon-applicable (NA).
TABLe 3 | Characteristics of all reported infants without underlying 
disorders, invasively infected with Cronobacter, by time period.
Characteristica 1958–2003 2004–2010 Total P valueb
Premature 48/63 (76%) 12/29 (41%) 60/92 (65%)
Full term 15/63 (24%) 17/29 (59%) 32/92 (35%) P = 0.002
BW <2500 g 44/55 (80%) 10/24 (42%) 54/79 (68%)
BW ≥ 2500 g 11/55 (20%) 14/24 (58%) 25/79 (32%) P = 0.001
Place of symptom onset:
 Hospital 48/61 (79%) 14/29 (48%)c 62/90 (69%)
 Home 13/61 (21%) 15/29 (52%) 28/90 (31%) P = 0.007
aAn infant was considered full term if the records indicated that was the case and/or 
the gestational age was specified as being at least 37 weeks. An infant was considered 
premature if the records indicated that was the case and/or the gestational age was 
less than 37 weeks. BW, birthweight. Table excludes patients for whom the specified 
data are unknown; there were a total of 68 infants in 1958–2003 and 30 in 2004–2010.
bFisher’s exact tests and Freeman-Halton extension of the Fisher’s exact probability test 
for a 2 × 3 table. Not significant (NS) if P ≥ 0.05. Totals percents may not equal 100 
due to rounding.
cThis category includes one infant who became ill 12 h after leaving the hospital and 
another who was noted to be ill on the day of hospital discharge and was reportedly 
symptomatic while in the hospital.
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not shown). This combination of findings supports that invasive 
infections can occur in healthy newborns and the proportion 
of cases in this group increased in the years following the FDA 
recommendation to avoid feeding PIF to hospitalized infants.
The third study addressed the relative costs two alternative 
forms of infant formula, RTF and concentrates, compared to 
PIF. A cross-sectional survey was done in September 2011. It 
compared on-line-prices for six formulas commonly used from 
birth to 6 or 12  months of age and available in PIF, RTF, and 
concentrate formulations. Prices varied relatively widely within 
and among brands, products, formulations, and stores. The 
approximate daily (four ounces of formula every 4 h) costs for 
feeding a neonate the least expensive formula of each type were 
calculated and compared. Details are provided in the footnotes to 
Table 4. The results support that if an infant’s caretaker was not 
brand-committed, the cost of RTF did not differ meaningfully 
from the cost of PIF. Specifically, milk-based RTF costs only 84 
cents more a day than milk-based PIF and soy-based RTF costs 
24 cents less a day than soy-based PIF (Table 4).
The following consumer recommendation appeared on CDC’s 
Cronobacter webpage in December 2012: “If your baby gets for-
mula, choose infant formula sold in liquid form, especially when 
your baby is a newborn or very young”4. Unfortunately, CDC’s one 
epidemiologic contribution to the recent Cronobacter literature, a 
2014 article by Patrick et al. published in CDC’s journal Emerging 
Infectious Diseases, not as insightful (49). It is seriously flawed and 
misleading in a number of respects but this editorial review will 
focus on a few key issues.
The 2014 Patrick/CDC study examined data collected 
through CDC’s FoodNet Program [Foodborne Diseases Active 
Surveillance Network (FoodNet)] (50), an excellent labora-
tory isolate surveillance program but one that does not collect 
detailed patient information. The FoodNet data support what 
4 http://www.cdc.gov/cronobacter/investigation.html#advice
was previously known: with rare exception, clinical Cronobacter 
isolates come from the very young and the very old. Despite 
that bimodal distribution, Patrick et al. stated that the median 
age for Cronobacter disease is 59 years, a number that has been 
widely quoted by the lay press and formula manufacturers’ rep-
resentatives. As the authors surely knew, a median misrepresents 
a bimodal distribution. In the case of Cronobacter, it implies that 
middle-aged people are at risk of Cronobacter infection. That 
is precisely not the case – but it is a “statistic” which the CDC 
authors provided in their article and which PIF manufacturers’ 
lawyers can now use as evidence that late-middle-aged adults may 
transmit Cronobacter to their grandchildren.
Cronobacter infections are rare in both infants and adults but 
the similarity stops there. An equally egregious flaw in this often-
cited article is that it obfuscates at least three distinct differences 
between Cronobacter infections in children and Cronobacter 
infections in adults. First, evidence increasingly supports that 
they are caused by different Cronobacter species and strains and 
the sources of these strains are different. Evidence to date strongly 
indicates that PIF is the primary source of invasive infections in 
young infants. The sources of infection/colonization in adults are 
unknown but these infections are likely transmitted nosocomially 
(i.e., through exposures related to their hospitalization and hos-
pital care) and/or through contaminated nutrition these adults 
are receiving. Second, Cronobacter infections occur in previously 
healthy infants. Virtually all Cronobacter infection and coloniza-
tion of adults occur in immunocompromised, elderly, and/or 
hospitalized adults who are ill with more significant infections 
FiGURe 2 | Peter Paul Rubens’ rendering of Cronus devouring his 
son, Poseidon.
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and/or illnesses. Third, in infants, Cronobacter can cause menin-
gitis, sepsis, and death. In adults, Cronobacter is an opportunistic 
organism that merely colonizes the patient or causes symptoms 
that are insignificant in comparison to that adult’s underlying 
medical problem and other infections. The authors compare 
apples to oranges when they state, “the highest rates occurred 
among persons ≥80 years of age, followed by persons 70–79 years 
of age and infants” (49).
Thanks to this article and CDC’s related website verbiage (51), 
the press, other authors, and public health agencies now parrot 
the phrase “Cronobacter infection occurs more frequently in 
adults than children.” This ignores the elephant-in-the-room, 
an elephant that is reflected in the very name of the genus: 
i.e., Cronobacter was named after Cronos, the Greek god who 
devoured his own children (Figure 2). Patrick et  al.’s final rec-
ommendation concerning Cronobacter disease in adults is that 
“routine, systematic surveillance and special studies will be essential 
for understanding these findings, identifying reservoirs of infection 
and vehicles of transmission, and developing effective prevention 
and control measures.” Cronobacter is a rare infection; realistically, 
special studies would take decades and be expensive at a time 
when research dollars are scarce.
Rather than start from scratch, it would behoove CDC to iden-
tify and consolidate the many Cronobacter isolates it has obtained 
over the last 60+ years. One would expect that these isolates 
and their associated epidemiologic data have been safely stored. 
Patrick’s stated goals would be better and more efficiently served 
by testing those isolates using Baldwin’s MLST scheme and Tall’s 
pan genomic DNA microarray platform and analyzing the results.
U.S. Centers for Disease Control and Prevention appears to 
have thus far ignored the recent Cronobacter research related to 
strain typing and contamination distribution in PIF products. 
What, then, has been the response of other health agencies? This 
Frontiers Topic editorial review will end with an examination of 
the related current policies of three institutions: the FDA, the U.S. 
Special Supplemental Nutrition Program for Women, Infants, 
and Children (WIC), and the WHO.
By legal mandate, the FDA must oversee manufacturers of 
infant formulas and help ensure that these products are safe and 
support healthy growth in infants who consume them. On June 
9, 2014 it finalized a rule that set standards for manufacturers of 
infant formula. Manufacturers had to comply with that rule as 
of September 8, 2014 (47). The new rules have, in general, eased 
FDA oversight of PIF manufacturing but the FDA has updated its 
protocol for testing end-products, including changing its statis-
tical sampling plan to be in accordance with Dr. Jongenburger’s 
recommendations (44). The FDA notes that, with this sampling 
plan, “when the production aggregate (FDA’s new term for a lot 
or batch) is sampled and the composite is tested, if the pathogen is 
not detected, the manufacturer has a 95% level of confidence that 
there would be <1 CFU Cronobacter spp. in 100 g powder” (52). 
That, of course, continues to ignore the practical significance of 
Cronobacter’s clumping. Also, it merits noting that a 95% level 
of confidence means that, assuming the confidence interval/
hypothesis test is one-sided, there is up to approximately a 5% 
chance of a type I error, i.e., that a production aggregate testing 
negative with FDA’s proposed testing scheme might actually 
contain ≥1  CFU Cronobacter  spp. in 100  g powder but be 
released to market. This probability is indeed very low but since 
thousands of production aggregates are released to market each 
year, this risk is not inconsequential. If a released aggregate con-
tains one or more contaminating clumps or clusters of a strain 
or sequence type that can produce invasive infection (e.g., ST4 
or a virulent serogroup) and these clumps are fed to a young, 
susceptible infant, the consequences can be devastating.
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Despite data to the contrary, on its “Consumer Update Page,” 
the FDA places RTF third on its list of three formula options 
and provides the following description of that option: “Ready-to-
feed – the most expensive form of formula that requires no mixing” 
(47). Following the 2011 Cronobacter cases, the WIC Program 
reviewed its policies and decided to continue to preferentially 
support PIF over RTF, even in the first 2  months of life. WIC 
provides Federal grants to States for supplemental foods for 
approximately half of all U.S. infants. Parents on WIC cannot 
comparison shop; they must take what WIC provides them. WIC 
purchases infant formula at a discount, through a state-by-state 
exclusive contract bidding process, and provides that formula to 
non-breastfeeding or breast milk-supplementing mothers. WIC 
provides PIF to these mothers (53) and WIC programs instructs 
physicians to prescribe RTF only under certain, specific condi-
tions, for their clients on WIC [e.g., Ref. (54)5].
The World Health Organization’s current recommendations 
related to Cronobacter are that PIF be reconstituted with water 
that has been boiled and then cooled to 70°C, to inactivate any 
Cronobacter contaminating the PIF (55, 56). There are at least 
three problems with this recommendation, one of which was 
highlighted in Dr. Parra Flores’ Frontiers Topic manuscript (35). 
First, it is unlikely that this recommendation will be accurately 
followed in a home setting. Few caretakers will routinely measure 
5 https://www1.maine.gov/dhhs/mecdc/health-equity/wic/documents/health-
RTFricestarchformulas.pdf
the temperature of boiled water before they mix it with PIF. The 
time required will vary with ambient temperature. If the water 
is cooled too long, the previously boiled, now warm water will 
incubate contaminating Cronobacter, not kill it. Second, some 
organizations disagree with this recommendation because of 
concerns that it may destroy heat-sensitive nutrients, change 
some formulas’ physical characteristics, cannot be accurately 
followed in a real-world setting, and/or because the hot water 
could injure personnel preparing the formula (21). Third, the 
rehydration instructions on some PIF labels do not comply with 
WHO guidelines.
CONCLUSiON
In an ideal world, medical, laboratory, and epidemiologic 
researchers and health agencies work hand-in-hand to further 
scientific knowledge and apply that knowledge to benefit society. 
In the past, in regard to Cronobacter, this interaction was more or 
less ideal and led to significant progress. In recent years, labora-
torians have been doing more than their fair share. It is time for 
epidemiologists and health agencies to view this issue with fresh 
eyes and step up to the plate.
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